Biotech entity
Azilsartan Medoxomil Tablets is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. The average consequence score is 6, matching the 6 beat baseline for this window.
Last mentioned: Jul 31, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Azilsartan Medoxomil Tablets is the most frequent co-covered peer, appearing in 1 of the 2 tracked stories. Each story carries 2 original sources on average, compared with 2.5 for the broader beat in this window. The average consequence score is 6, matching the 6 beat baseline for this window. Coverage clusters in clinical-trial, which accounts for 1 of those 2, with the remainder spread across 1 other category. We currently track 2 Biotech stories that mention Lupin Limited, published between July 27, 2026 and July 31, 2026.
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 29 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Lupin Limited. Shared-story counts are live from our verified record — not editorial picks.
Spin-Out Announcement
Lupin announced the spin-out of LNP7457 and LNP8701 into Kaveri Therapeutics, along with the leadership appointments and funding structure.
LNP8701 ASCO Data
Lupin presented positive clinical data for the SOS1 inhibitor LNP8701 at the 2026 ASCO annual meeting.
LNP7457 ASCO Data
Lupin presented positive clinical data for the PRMT5 inhibitor LNP7457 at the 2025 ASCO annual meeting.
Lupin launches its generic azilsartan medoxomil in the U.S., capturing first-to-file exclusivity for a $53.5 million hypertension drug market. The move strengthens Lupin’s cardiovascular pipeline and could deliver a revenue boost during the 180-day exclusivity window.
Source: prnewswire.com · montrealgazette.com
Lupin’s oncology pipeline yields a new standalone startup, Kaveri Therapeutics, built around PRMT5 inhibitor LNP7457 and SOS1 inhibitor LNP8701. Both compounds showed encouraging clinical data at ASCO 2025 and 2026, and the biotech will now seek external funding to advance global trials.
Lupin Limited is linked from 2 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
